MEDIGEN, INC.  

Medigen, Inc. is a biotechnology company that specializes in biomedical research in the areas of infectious diseases, cancer, and human gene therapy.

Our expertise is primarily in cancer vaccines and vaccines against emerging and biodefense diseases.

Our research is focused on Virus-Like Particles (VLPs) as vaccines as well as vaccine vectors. Medigen also develops new ways of vaccine delivery for effective and safe immunization.

What We Do

Medigen, Inc. conducts active scientific research in the areas of infectious diseases, cancer, and gene therapy.

We have applied our expertise in virus vectors and virus-like particles for the development of new vaccine candidates against human immunodeficiency virus (HIV), hepatitis B virus (HBV), human papilloma virus (HPV) and influenza virus.

We also provide our clients with expert consulting services and contract research in these fields, including experiment design, intellectual property development, and publishing and communicating data to the scientific community and government agencies. Please contact us for further details or request a quote at

info@medigen-usa.com

           

What's New?

In recent months, we had several important developments. To name just a few:

• We've prepared scientific article for publication in a peer reviewed biomedical journal
• We've engaged with a leading national law firm for intellectual property development 
• We've developed a novel, biologically safe vector platform for vaccine and gene therapy applications
• We've adviced members of scientific community and government agencies in the areas of vaccines for human immunodeficiency virus (HIV), influenza virus, hepatitis B virus (HBV), as well as for biodefence-relevant agents such as anthrax, Ebola, and Marburg viruses.